Novocure terminates LUNAR-4 lung cancer trial

Novocure (NASDAQ: NVCR) announced that its subsidiary Novocure GmbH has decided to terminate the LUNAR-4 clinical trial, according to a company statement.

The company notified trial sites of the termination on August 28, 2025. LUNAR-4 was a phase 2, single arm, open-label, multinational study examining Tumor Treating Fields used alongside pembrolizumab for treating metastatic non-small cell lung cancer in patients previously treated with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy.

The company stated that the availability of real-world evidence will allow it to achieve the objectives of LUNAR-4 without conducting an interventional clinical study. Novocure emphasized that the decision was not related to any safety concerns.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• Crusoe in talks to raise $3B in funding - Bloomberg
• VivoPower shifts focus to AI data centers, revises unit spinoff plans